Nelarabine

證據等級: L5

預測適應症: 1 個

Nelarabine: From T-cell Acute Lymphoblastic Leukemia to Relapsing-Remitting Multiple Sclerosis

One-Sentence Summary

Nelarabine is a purine nucleoside analog chemotherapy agent originally developed for relapsed/refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. The TxGNN model predicts it may be effective for relapsing-remitting multiple sclerosis, but this prediction is currently supported by no registered clinical trials and no published literature — it rests on the model score alone.

Quick Overview

Item	Content
Original Indication	T-cell acute lymphoblastic leukemia (T-ALL) / T-cell lymphoblastic lymphoma (T-LBL) (general background knowledge — not present in the Norway license data, as the drug is not marketed there)
Predicted New Indication	Relapsing-remitting multiple sclerosis
TxGNN Prediction Score	99.43%
Evidence Level	L5
Norway Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack. Based on general background knowledge, nelarabine is a prodrug of 9-β-D-arabinofuranosylguanine (ara-G), a purine nucleoside analog that is selectively phosphorylated and accumulates in T-lymphoblasts, causing DNA-strand breaks and cell death. Its clinical efficacy in T-ALL/T-LBL is well established, but this mechanism is directed at proliferating malignant T-cells rather than the autoimmune/neuroinflammatory processes underlying multiple sclerosis.

There is no direct mechanistic or clinical rationale in the evidence pack linking nelarabine's cytotoxic, T-cell-depleting activity to relapsing-remitting MS. While selective T-cell cytotoxicity is a shared theme with some MS immunomodulators (e.g., cladribine, another purine analog approved for MS), nelarabine's known neurotoxicity profile is a significant concern for use in a neurological disease population. This prediction should be treated as a model-generated hypothesis requiring substantial mechanistic and preclinical validation before further consideration.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Norway Market Information

Nelarabine currently has no marketing authorization in Norway (0 licenses on record); no product or indication data is available for this market.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (purine nucleoside analog / antimetabolite — prodrug of ara-G)
Myelosuppression Risk	High — neutropenia, thrombocytopenia, and anemia are commonly reported; nelarabine also carries a distinct risk of severe neurotoxicity (peripheral neuropathy, somnolence, seizures)
Emetogenicity Classification	Low to moderate
Monitoring Items	CBC with differential, neurological status assessment (due to neurotoxicity risk), liver and renal function
Handling Protection	Must follow cytotoxic/hazardous drug handling regulations (USP <800> or equivalent)

Note: The above is based on general pharmacological knowledge of nelarabine, as no drug-specific toxicity data was provided in this evidence pack (see Data Gap DG002).

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction is supported only by a TxGNN model score (L5), with zero clinical trials or literature evidence, no MOA data, no Norway market presence, and unresolved safety data gaps (including TFDA-equivalent labeling, a Blocking-severity gap). There is currently no basis to move this candidate forward.

To proceed, the following is needed:

Mechanism of action data to assess plausibility for a neuroinflammatory indication (DG002)
Official warnings/contraindications/label data (DG001, Blocking)
Any preclinical or exploratory clinical evidence linking nelarabine to MS or related autoimmune neurological conditions
Confirmation of original indication and regulatory status from a validated source
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.